FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135225325> ?p ?o ?g. }

• W3135225325 endingPage "289" @default.
• W3135225325 startingPage "280" @default.
• W3135225325 abstract "It is highly tempting to develop high-efficacy targeted nanotherapeutics based on FDA approved polymers like PLGA. Herein, we describe facile fabrication of robust, hyaluronic acid-surfaced and disulfide-crosslinked star-PLGA nanoparticles (HA-sPLGA XNPs) for targeted and reduction-triggered release of docetaxel (DTX), achieving markedly enhanced treatment of A549 lung tumor in vivo. HA-sPLGA XNPs carrying 5.2 wt.% DTX (DTX-HA-sPLGA XNPs) had a size of 105.5 ± 0.5 nm and great stability while almost completely released DTX under 10 mM glutathione. Confocal and flow cytometry experiments revealed fast cellular uptake of HA-sPLGA XNPs by CD44-overexpressing A549 cells. DTX-HA-sPLGA XNPs held much higher potency to A549 cells than DTX-loaded HA-surfaced and non-crosslinked star-PLGA nanoparticles (DTX-HA-sPLGA NPs), DTX-loaded HA-surfaced and non-crosslinked linear-PLGA nanoparticles (DTX-HA-lPLGA NPs), and free DTX (IC50 = 0.18 versus 0.38, 1.21 and 0.83 µg DTX equiv./mL). Intriguingly, DTX-HA-sPLGA XNPs revealed a prolonged elimination half-life of 4.18 h and notable accretion of 9.49%ID/g in A549 tumor after 8 h injection. Accordingly, DTX-HA-sPLGA XNPs demonstrated significantly better suppression of subcutaneous A549 lung tumor than DTX-HA-PLGA NPs, DTX-HA-lPLGA NPs, and free DTX controls. HA-sPLGA XNPs with low toxicity and multi-functionality appear to be a unique targeted vehicle for chemotherapy of CD44-overexpressing tumors. PLGA nanoparticles with superior safety and biodegradability are among the most advanced vehicles for therapeutic delivery. The efficacy of nanomedicines based on PLGA is, however, suboptimal, due to poor tumor cell selectivity and uptake, drug leakage, and slow drug release at the pathological site. It is highly desired to develop functional PLGA nanoparticles to improve their tumor-targeting ability and therapeutic efficacy. The sophisticated fabrication and potential toxicity concerns of reported novel PLGA nanoformulations, nevertheless, preclude their clinical translation. Here, we developed hyaluronic acid-surfaced and disulfide-crosslinked star-PLGA nanoparticles (HA-sPLGA XNPs) that enabled stable encapsulation and targeted delivery of docetaxel (DTX) to CD44+ A549 lung cancer cells in vitro and in vivo, affording markedly improved tumor accumulation and repression and lower side effects compared with free DTX control. Importantly, HA-sPLGA XNPs are based on fully biocompatible materials and comparably simple to fabricate. The evident tumor targetability and safety makes HA-sPLGA XNPs a unique and potentially translatable platform for chemotherapy of CD44+ cancers." @default.
• W3135225325 created "2021-03-15" @default.
• W3135225325 creator A5039037778 @default.
• W3135225325 creator A5040007058 @default.
• W3135225325 creator A5058784587 @default.
• W3135225325 date "2021-04-01" @default.
• W3135225325 modified "2023-10-18" @default.
• W3135225325 title "Facile fabrication of robust, hyaluronic acid-surfaced and disulfide-crosslinked PLGA nanoparticles for tumor-targeted and reduction-triggered release of docetaxel" @default.
• W3135225325 cites W1909499926 @default.
• W3135225325 cites W1975813586 @default.
• W3135225325 cites W1977074396 @default.
• W3135225325 cites W1990450973 @default.
• W3135225325 cites W1996051333 @default.
• W3135225325 cites W2003474213 @default.
• W3135225325 cites W2007464324 @default.
• W3135225325 cites W2062684585 @default.
• W3135225325 cites W2072931565 @default.
• W3135225325 cites W2078336648 @default.
• W3135225325 cites W2089773350 @default.
• W3135225325 cites W2095782040 @default.
• W3135225325 cites W2099769368 @default.
• W3135225325 cites W2133943200 @default.
• W3135225325 cites W2155464400 @default.
• W3135225325 cites W2173044124 @default.
• W3135225325 cites W2216824414 @default.
• W3135225325 cites W2221696309 @default.
• W3135225325 cites W2272216542 @default.
• W3135225325 cites W2294999722 @default.
• W3135225325 cites W2324393204 @default.
• W3135225325 cites W2339017415 @default.
• W3135225325 cites W2344598639 @default.
• W3135225325 cites W2440457800 @default.
• W3135225325 cites W2461458897 @default.
• W3135225325 cites W2474056317 @default.
• W3135225325 cites W2495321584 @default.
• W3135225325 cites W2509149598 @default.
• W3135225325 cites W2544632459 @default.
• W3135225325 cites W2547765432 @default.
• W3135225325 cites W2563348753 @default.
• W3135225325 cites W2565452625 @default.
• W3135225325 cites W2568075194 @default.
• W3135225325 cites W2576905205 @default.
• W3135225325 cites W2621158682 @default.
• W3135225325 cites W2724769154 @default.
• W3135225325 cites W2759658096 @default.
• W3135225325 cites W2764045342 @default.
• W3135225325 cites W2780326442 @default.
• W3135225325 cites W2782822015 @default.
• W3135225325 cites W2789619448 @default.
• W3135225325 cites W2796802411 @default.
• W3135225325 cites W2797531413 @default.
• W3135225325 cites W2799739706 @default.
• W3135225325 cites W2806713886 @default.
• W3135225325 cites W2885226514 @default.
• W3135225325 cites W2894282608 @default.
• W3135225325 cites W2898712541 @default.
• W3135225325 cites W2943940643 @default.
• W3135225325 cites W2947395190 @default.
• W3135225325 cites W2948525863 @default.
• W3135225325 cites W2952771691 @default.
• W3135225325 cites W2969540689 @default.
• W3135225325 cites W2976932084 @default.
• W3135225325 cites W2978426541 @default.
• W3135225325 cites W2980929568 @default.
• W3135225325 cites W2998617594 @default.
• W3135225325 cites W3025080581 @default.
• W3135225325 cites W4234162823 @default.
• W3135225325 doi "https://doi.org/10.1016/j.actbio.2021.02.044" @default.
• W3135225325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33677162" @default.
• W3135225325 hasPublicationYear "2021" @default.
• W3135225325 type Work @default.
• W3135225325 sameAs 3135225325 @default.
• W3135225325 citedByCount "28" @default.
• W3135225325 countsByYear W31352253252021 @default.
• W3135225325 countsByYear W31352253252022 @default.
• W3135225325 countsByYear W31352253252023 @default.
• W3135225325 crossrefType "journal-article" @default.
• W3135225325 hasAuthorship W3135225325A5039037778 @default.
• W3135225325 hasAuthorship W3135225325A5040007058 @default.
• W3135225325 hasAuthorship W3135225325A5058784587 @default.
• W3135225325 hasConcept C105702510 @default.
• W3135225325 hasConcept C12554922 @default.
• W3135225325 hasConcept C141071460 @default.
• W3135225325 hasConcept C150903083 @default.
• W3135225325 hasConcept C155672457 @default.
• W3135225325 hasConcept C171250308 @default.
• W3135225325 hasConcept C185592680 @default.
• W3135225325 hasConcept C192562407 @default.
• W3135225325 hasConcept C202751555 @default.
• W3135225325 hasConcept C207001950 @default.
• W3135225325 hasConcept C2776694085 @default.
• W3135225325 hasConcept C2777529286 @default.
• W3135225325 hasConcept C2780165375 @default.
• W3135225325 hasConcept C2780932548 @default.
• W3135225325 hasConcept C2781190966 @default.
• W3135225325 hasConcept C55493867 @default.
• W3135225325 hasConcept C71924100 @default.
• W3135225325 hasConcept C81729549 @default.

• next